ValuEngine lowered shares of Neuralstem, Inc. (NASDAQ:CUR) from a hold rating to a sell rating in a research report report published on Tuesday.

Shares of Neuralstem (NASDAQ:CUR) traded down 5.14% during midday trading on Tuesday, hitting $1.66. 700,087 shares of the company were exchanged. The company has a 50-day moving average of $5.16 and a 200 day moving average of $4.62. Neuralstem has a one year low of $0.19 and a one year high of $6.60. The company’s market capitalization is $19.75 million.

WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/neuralstem-inc-cur-cut-to-sell-at-valuengine/1461605.html.

In other Neuralstem news, CEO Richard J. Daly bought 7,500 shares of the stock in a transaction on Wednesday, May 17th. The stock was purchased at an average price of $4.00 per share, with a total value of $30,000.00. Following the completion of the purchase, the chief executive officer now owns 23,312 shares in the company, valued at $93,248. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 19.25% of the stock is currently owned by insiders.

A hedge fund recently bought a new stake in Neuralstem stock. Alethea Capital Management LLC bought a new stake in Neuralstem, Inc. (NASDAQ:CUR) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 164,394 shares of the company’s stock, valued at approximately $868,000. Alethea Capital Management LLC owned 1.49% of Neuralstem at the end of the most recent reporting period. 12.46% of the stock is currently owned by institutional investors.

About Neuralstem

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.